f STI-571 seems to be very promising. “On the other hang, one has to be a little careful.” This leukemia has shown that even though it is the most known about that it also has a tendency to fluctuate. Shifts between remission to recurrence can occur completely unpredictably ( 372). Before becoming to optimistic about this new form of treatment it is impeccable that we realize that it is still in a new state. The long term affects are still questionable and remission is still impossible. However before excluding STI-571 it is important to evaluate if you are a good candidate for treatment and whether the risks are worth the hopes of complete remission. Chronic myelogenous leukemia results from an acquired not inherited injury to the DNA stem cell in the marrow. Scientists do not yet understand what produces this change in the DNA of CML patients. Scientists do express that as the human genome unfolds, cancer-related genes with unquestionable be identified and then gene products will be developed, such as insulin for diabetes, for maintenance of steady state environment in cancer patients, while gene therapy in some form or other dedicated to switching off an oncogene or repairing a rumor suppressor will come of age. There is much to hope for in following years. The difference between the end of the millennium and the beginning of the last quarter is that eventually we will be able o refine tailor-made treatments designed to match an individual patient’s tumor. Works CitedHagop, Kantarjian, ed. Leukemia Insights Newsletter. The University of Texas MD Anderson Cancer Center. v4n3 Winter 1999: 1-3.Henderson, Charles W. “Stem Cell Transplants Found Superior.” Journal of American Medical Association v283 n7 16 February 2000: 305-308.Kumar, Lalit and Subhash C. Gulati. “Alpha-interferon in Chronic Myelogenous Leukemia.” The Lancet v346 n8981 14 October 1995: 984-985.McConnaughe...
